Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Kosa KM, Cates SC, Hall AJ, Brophy JE, Frasier A. Knowledge of norovirus prevention and control among infection preventionists. Poster presented at the 2014 APIC’s 41st Annual Conference; June 2014. Anaheim, CA. [abstract] Am J Infect Control. 2014 Jun; 42(6):676-8. doi: 10.1016/j.ajic.2014.02.004
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulos G. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011 May 1;39(4):e15-20.
Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control. 2010 Feb;38(1):44-9. doi: 10.1016/j.ajic.2009.04.287.